Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes-Reference-Cited by-同舟云学术

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes

Published:2014-02-19 Issue:11 Volume:22 Page:1305-1313
ISSN:1018-4813
Container-title:European Journal of Human Genetics
language:en
Short-container-title:Eur J Hum Genet

Author:

Castéra Laurent,Krieger Sophie,Rousselin Antoine,Legros Angélina,Baumann Jean-Jacques,Bruet Olivia,Brault Baptiste,Fouillet Robin,Goardon Nicolas,Letac Olivier,Baert-Desurmont Stéphanie,Tinat Julie,Bera Odile,Dugast Catherine,Berthet Pascaline,Polycarpe Florence,Layet Valérie,Hardouin Agnes,Frébourg Thierry,Vaur Dominique

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Genetics

Link

http://www.nature.com/articles/ejhg201416.pdf

Reference40 articles.

1. Miki Y, Swensen J, Shattuck-Eidens D et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.

2. Wooster R, Bignell G, Lancaster J et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–792.

3. Antoniou A, Pharoah PD, Narod S et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–1130.

4. Tutt A, Robson M, Garber JE et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235–244.

5. Audeh MW, Carmichael J, Penson RT et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–251.

Cited by 206 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Testing of Breast Cancer Patients with Very Early-Onset Breast Cancer (≤30 Years) Yields a High Rate of Germline Pathogenic Variants, Mainly in the BRCA1, TP53, and BRCA2 Genes;Cancers;2024-06-27

2. Germline mutations in young-onset sporadic pituitary macroadenomas: a multigene panel analysis;2024-06-04

3. Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI];Current Women s Health Reviews;2024-02

4. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing;Pathology - Research and Practice;2024-02

5. HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis;Therapeutic Advances in Medical Oncology;2024-01